Shake-Up at FDA: Tracy Beth Hoeg Expected to Leave Amid Vaccine Policy Controversy

Tracy Beth Hoeg, acting head of the FDA's drug center, is set to depart just after Commissioner Marty Makary's resignation. Hoeg, an outspoken critic of COVID vaccines, played a key role in proposing changes to the U.S. childhood vaccination schedule. A broader shake-up in the health department is underway as new leadership seeks conventional appointees.

Tracy Beth Hoeg, the acting head of the U.S. Food and Drug Administration's drug center, is anticipated to exit the agency shortly following the resignation of Commissioner Marty Makary. Hoeg's tenure was marked by controversy as she advocated for significant changes to the U.S. childhood vaccination schedule, reducing the recommended shots from 17 to 11. However, these changes have been stalled due to legal challenges under Health Secretary Robert F. Kennedy's oversight.

The Health and Human Services Department and the FDA have refrained from commenting on these personnel shifts, but insiders suggest that Hoeg's departure is imminent amid a broader administrative restructure. The White House, keen on maintaining voter confidence ahead of crucial midterm elections, has been steering the health department towards more traditional leadership appointments. Chris Klomp, who recently joined as Kennedy's deputy, has been instrumental in nominating conventional figures for influential health roles, including posts at the CDC and for the Surgeon General.

Amidst these developments, several other FDA officials linked to Makary's leadership, such as Jim Traficant, Samuel Doran, and Sanjula Jain-Nagpal, are also thought to be on their way out. These potential depatures are part of a strategic move to stabilize the agency, after a period marked by high-profile exits and policy turmoil under Elon Musk's government efficiency initiative. Hoeg's brief tenure also included contentious decisions regarding vaccine labeling and drug approvals, which often put her at odds with FDA scientists.